The market for intravenous solutions was valued at US$ 11.3 billion in 2021 and is anticipated to grow at a CAGR of 7.7% from 2023 to 2032.
Intravenous solutions are administered to a patient when oral consumption of food and water is not possible due to several medical conditions and in case of organ failure. The demand for intravenous solutions is growing due to increasing number of patients with chronic kidney disorders, end-stage renal disease (ESRD), oral & esophagus cancer, and other similar medical conditions.
A patient is not capable to consume food and water during and after treatment of these medical conditions, thereby, the nutrients are supplied by means of intravenous solutions.
According to National Kidney Foundation, in the United States approximately 15% of the American adults were affected with chronic kidney disorders in 2016 and over 500,000 patients received dialysis treatment. The number of patients suffering with kidney failure are increasing globally and are anticipated to fuel the demand for intravenous solutions during coming years.
Additionally, rising geriatric population and improved healthcare facilities has increased the life expectancy of elderly population. As a result, Asia Pacific is expected to be the fastest growing geography during the forecast period.
The report titled “Intravenous Solutions Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global intravenous solutions market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, security & exchange overview, research & development activities, production facilities, product portfolio, employee strength, and key executive, for all the major players operating in the market. For instance, B. Braun Melsungen Ag reported revenues of US$7462.4 million in 2018 and the segment and geographic analysis of the company indicates that B. Braun Hospital Care business segment of the company dominated revenue in 2018 with Germany and North America being the major revenue generating geographies.
The global intravenous solutions market is segmented based on solution type, bag capacity, application, end user, and geography. Based on solution type, the global intravenous solutions market is segmented into saline, dextran, lactated ringer’s, amino acid, vitamins & minerals, heparin and trace elements, and mixed solutions. The saline solution type is further sub-segmented into normal saline (0.9% NaCl), and hypertonic saline. Based on bag capacity, the global intravenous solution market is segmented into small volume bags (less than 250ml), and large volume bags (greater than 250 ml). Based on application, the global intravenous solution market is segmented into basic intravenous solution, nutritional intravenous solution, blood intravenous solution, drug intravenous solution, and irrigation intravenous solution. Based on end user, the global intravenous solution market is segmented into hospitals, clinics, ambulatory surgery centers, and home care settings. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
Additionally, the study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the intravenous solutions companies. Further, market share of prominent companies in the global Intravenous Solutions market would also be estimated.
For instance, B. Braun Melsungen Ag operates through four business divisions namely B. Braun Aesculap, B. Braun OPM, B. Braun Avitum, and B. Braun Hospital Care. The intravenous solutions are delivered under B. Braun Avitum business division of the company with revenue contribution of US$ 1168.8 Million in 2018.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the intravenous solutions companies. Furthermore, the global intravenous solutions market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
The product portfolio would focus on all the products under the intravenous solutions market business segment of the company. Similarly, the recent development section would focus on the latest developments of a company such as strategic alliances and partnerships, merger and acquisition, a new product launched and geographic expansion in the global intravenous solutions market arena.
Major players operating the global intravenous solutions market include Amanta Healthcare, Axa Parenterals Ltd., B. Braun Melsungen Ag, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical, Inc., JW Life Science, Salius Pharma Private Limited, and Vifor Pharma Management Ltd.
The Global Intravenous Solutions Market Is Segmented As Below:
Based On Solution Type
Based On Bag Capacity
Based On Application
Based On End User
By Geography:
The base year considered in intravenous solutions market report is 2022.
Major players operating in the intravenous solutions market include Amanta Healthcare, Axa Parenterals Ltd., B. Braun Melsungen Ag, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical, Inc., JW Life Science, Salius Pharma Private Limited, and Vifor Pharma Management Ltd.
The intravenous solutions market is estimated to exhibit a CAGR of 7.7% from 2023 to 2032.
The average lifespan of the elderly population has also increased due to the growing geriatric population and better healthcare services. Asia Pacific is therefore anticipated to experience the largest growth during the projection period.
Due to an increase in patients with end-stage kidney impairment (ESRD), mouth and esophageal cancer, as well as other related medical problems, there is a growing market for intravenous treatments.
The intravenous solutions market was valued at US$ 11.3 billion in 2021.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved